The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1483
December 7, 2015
View Complete Issue         Table of Contents 2019 
Issue 1483
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
December 7, 2015 (Issue: 1483)
The FDA has approved insulin degludec (Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the FDA; insulin detemir (Levemir) and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1483
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.